-
Dolutegravir more likely to suppress very high viral loads than other recommended first-line drugs
14 Sep 2021 08:08 GMT
… .
Inability of a medical therapy to achieve the … drug resistance, poor adherence to an HIV treatment regimen or interrupting treatment. … the protease inhibitor darunavir (Prezista, also in Rezolsta or … so that doctors can judge which core drugs are likely …
-
Antiretroviral Drugs Market Size Trends, Emerging Growth Factors and Regional Forecast to 2030
26 Aug 2021 06:53 GMT
… HIV AIDS, growing antiretroviral treatment coverage rate, and increase in availability of novel drugs … with better efficacy. Moreover, factors such as growing medical spending … : Edurant(R).
o Protease Inhibitors: PREZISTA (R) /PREZCOBIX(R) …
-
Antiretroviral Drugs Market 2021 Global Industry Size, Share, Analysis, Development, Revenue, Future Growth, Business Prospects and Forecast to 2030
29 Jul 2021 04:17 GMT
… HIV AIDS, growing antiretroviral treatment coverage rate, and increase in availability of novel drugs … with better efficacy. Moreover, factors such as growing medical spending … : Edurant(R).
o Protease Inhibitors: PREZISTA (R) /PREZCOBIX(R) …
-
Antiretroviral Drugs Market 2021 Comprehensive Research Methodology, Regional Study and Business Operation Data Analysis by 2030
06 Jul 2021 06:16 GMT
… HIV AIDS, growing antiretroviral treatment coverage rate, and increase in availability of novel drugs … with better efficacy. Moreover, factors such as growing medical spending … : Edurant(R).
o Protease Inhibitors: PREZISTA (R) /PREZCOBIX(R) …
-
Spanish studies highlight scale of late presentation and its consequences for treatment
24 Jun 2021 06:05 GMT
… , published in AIDS, found that HIV treatment is less effective … with acquiring HIV through injecting drug use or heterosexual … often excluded from clinical trials.
Accordingly, Dr Rava … + Rezolsta, or Truvada + Prezista + Norvir)
tenofovir disproxil fumarate…
-
Antiretroviral Drugs Market 2021 Trending Technologies, Development Plans, Future Growth and Geographical Regions to 2030
18 Jun 2021 04:44 GMT
… HIV AIDS, growing antiretroviral treatment coverage rate, and increase in availability of novel drugs … with better efficacy. Moreover, factors such as growing medical spending … : Edurant(R).
o Protease Inhibitors: PREZISTA (R) /PREZCOBIX(R) …
-
UIC's first-of-its-kind contraceptive receives FDA approval
19 Aug 2020 23:39 GMT
… Zaneveld of Rush University Medical Center. Development of … use through clinical trials and FDA approvals.
According … FDA-approved therapies.
Prezista, the first treatment for multi-drug resistant HIV, … licensed the vaccine to pharmaceutical company GSK.
Tice …
-
Coronavirus Business Impact: Antiretroviral Drugs Market Report 2020-2023| Industry Trends And Analysis
03 Aug 2020 08:02 GMT
… HIV AIDS, growing antiretroviral treatment coverage rate, and increase in availability of novel drugs … with better efficacy. Moreover, factors such as growing medical spending … : Edurant(R).
o Protease Inhibitors: PREZISTA (R) /PREZCOBIX(R) …
-
European advisory backs expanded label for J&J's HIV med Prezista
24 Jul 2020 17:00 GMT
The European Medicines Agency's advisory group … 's (JNJ -1.2%) Prezista (darunavir) when co-administered with …
-
<![CDATA[COVID-19: 155 drugs and 79 vaccines under development worldwide]]>
22 Apr 2020 18:48 GMT
… for coronaviruses – pharmaceutical and biotech companies, university institutes … ®), Favipirvir (Avigan®), Darunavir (Prezista®), Chloroquine phosphates (Resochin®), Hydroxychloroquine … claim, the European Medicines Agency (EMA) … for those drugs or vaccines …
About
© 1995-2021